Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

January 19, 2024

https://www.globenewswire.com/news-release/2023/11/17/2782524/0/en/Adlai-Nortye-Announces-Completion-of-Patient-Enrollment-in-Global-Phase-III-Clinical-Trial-of-Buparlisib-AN2025-in-Combination-with-Paclitaxel-for-the-Treatment-of-Recurrent-or-Met.html

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 17, 2023 (GLOBE NEWSWIRE) — Adlai Nortye Ltd. (NASDAQ:ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the Completion of Patient Enrollment in Global Phase III Clinical Trial (BURAN) of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC in more than 180 sites around the world, spanning over 18 markets in North America, Europe, Asia, and South America.

Read more at globenewswire.com

Related news for (ANL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.